Company Quick10K Filing
Vitalibis
10-K 2019-12-31 Filed 2020-03-13
10-Q 2019-06-30 Filed 2019-08-09
S-1 2019-05-16 Public Filing
10-Q 2019-03-31 Filed 2019-05-10
10-K 2018-12-31 Filed 2019-03-28
10-Q 2018-09-30 Filed 2018-11-05
10-Q 2018-06-30 Filed 2018-08-02
10-Q 2018-03-31 Filed 2018-05-11
10-K 2017-12-31 Filed 2018-04-10
10-Q 2017-09-30 Filed 2017-11-13
10-Q 2017-06-30 Filed 2017-08-10
10-Q 2017-03-31 Filed 2017-05-12
10-K 2016-12-31 Filed 2017-03-31
10-Q 2016-09-30 Filed 2016-11-09
10-Q 2016-06-30 Filed 2016-08-08
10-Q 2016-03-31 Filed 2016-05-11
10-K 2015-12-31 Filed 2016-03-18
10-Q 2015-09-30 Filed 2015-11-09
8-K 2019-11-18 Other Events, Exhibits
8-K 2018-11-15 Officers
8-K 2018-03-07 Enter Agreement, Regulation FD, Exhibits
8-K 2018-02-08 Amend Bylaw, Regulation FD, Exhibits
8-K 2018-01-18 Other Events, Exhibits
8-K 2018-01-02 Other Events, Exhibits
8-K 2018-01-02 Other Events

Vitalibis Financials

VCBD Metrics, Comps, Filings

Quarterly | Annual

Business

We are an emerging growth company as defined in Section 2(a)(19) of the Securities Act. We will continue to be an emerging growth company until: (i) the last day of our fiscal year during which we had total annual gross revenues of $1,000,000,000 or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (iv) the date on which we are deemed to be a large accelerated filer, as defined in Section 12b-2 of the Exchange Act.

Section 14A (a) and (b) of the Exchange Act, which requires companies to hold stockholder advisory votes on executive compensation and golden parachute compensation;

The requirement to provide in any registration statement periodic report or other report to be filed with the Securities and Exchange Commission, certain modified executive compensation disclosure under Item 402 of Regulation S-K or selected financial data under Item 301 of Regulation S-K for any period before the earliest audited period presented in our initial registration statement;


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarterly)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
XSport Global (TLLT) 13,108 39% -7.7 -312% 774 4,664 1,814 714 -2,418 -1,805 13,877
Rocky Mountain High Brands (RMHB) 6,308 -23% -1.7 354,870,400% 467 -108 -3,549 -4,176 6,891
Strategic Environmental & Energy Resources (SENR) 13,073 0% -11.6 -65% 3,038 8,740 4,192 0 -1,982 -1,154 13,379
Gilla (GLLA) 12,944 65% -3.1 -134% 4,303 12,570 4,388 2,873 -5,761 -4,419 13,882
FC Global Realty (FCRE) 170,563 86% -62.4 -2% 134,314 52,885 44 38 -2,748 -2,732 170,584
Advanzeon (CHCR) 27,618 70% -14.6 -100% 2,742 30,704 301 210 -2,746 -2,746 40,162
nDivision (NDVN) 14,399 80% -26.9 -44% 1,959 1,573 4,258 3,417 -863 -530 14,251
Black Box (BBOX) 12,647 27% 57.9 -21% 297,764 237,819 738,286 202,895 -63,375 1,605 92,921
GT Biopharma (GTBP) 11,372 -0.3 -7,713% 482 18,768 0 0 -37,177 -35,674 11,059
LifeApps Brands (LFAP) 11,714 100% -1.9 -8,113% 73 2,450 5 5 -5,899 -6,200 11,700
Vitalibis (VCBD) 8,075 42% -2.1 -894% 525 1,724 233 98 -4,694 -3,894 8,040
Inrad Optics (INRD) 12,499 19% -24.7 -9% 7,130 5,043 7,444 1,445 -671 -474 11,687
ETF Managers Group Commodity Trust I (RISE) 6,472 6.4 12% 8,210 25 0 0 1,009 1,009 6,472
Rangeford Resources (RGFR) 12,303 -16.3 -156,832% 1 2,524 0 0 -801 -801 13,102
Tofutti Brands (TOFB) 9,793 28% -171.6 -2% 5,114 1,443 9,766 2,735 -79 -54 9,266
CannaPowder (CAPD) 12,403 -5.6 -2,548% 86 0 0 0 -2,194 -2,194 12,334
Mymetics (MYMX) 12,150 0% -9.2 -45% 7,288 57,604 370 0 -3,304 -1,285 11,834
Curaegis Technologies (CRGS) 12,193 15% -8.8 -1,243% 284 11,804 13 2 -3,530 -2,550 22,368
Integral Technologies (ITKG) 12,094 0% -2.9 -922% 598 5,110 1,086 0 -5,514 -3,985 11,714
Enzon Pharmaceuticals (ENZN) 13,707 0% 2.9 -6% 12,070 5,753 158 0 -717 1,283 3,691

Balance Sheet ($'000)2015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash9200011000284325373172611234
Accounts Receivable0
Inventory73119189154293345
PP&E
Assets96413011000284570679570409437525
Accounts Payable5677650
Long-Term Debt
Liabilities708083971071257410562177461802367841,724
Stockholders' Equity-61-74-79-84-1070-24-74-105-6262493633390173-347-1,198
Income Statement ($'000)2015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue0000006301404053
Cost of Revenue000000215881828
Gross Profit000000514512225
R&D0000
SG&A132414153202450317464516402,448756294
Tax0000000000000000
Net Income-14-23-14-15-320-24-42-312-746-447-626-2,448-1,052-1,193
Cash Flow ($'000)2015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-17-5-15-1100-1-00-18-145-206-286-320-300
Cash Investing-81000
Cash Financing3151110000301270336175271322